CHRS Q1 2021 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$83M-28.5% YoY

Gross Profit

$76M91.0% margin

Operating Income

-$167M-201.6% margin

Net Income

-$173M-208.3% margin

EPS (Diluted)

$-2.37

QoQ Revenue Growth

-24.8%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

$1M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$693M

Total Liabilities

$566M

Stockholders' Equity

$128M

Cash & Equivalents

$259M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$116M	-28.5%
Gross Profit	$76M	$109M	-30.9%
Operating Income	-$167M	$41M	-509.5%
Net Income	-$173M	$36M	-586.2%

Revenue Segments

Product

$83M100%